Abstract: The present invention relates to a method for isolating and/or identifying stem cells having adipocytic, chondrocytic and pancreatic differentiation potential, wherein an antibody is used that binds to the antigen TNAP, alone or in combination with an antibody that binds to the cell surface antigen CD56. The invention also relates to stem cells isolated by the method according to the invention for treating defects or damages or diseases in bone or cartilage of a patient in need thereof.

Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.

Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on Aug. 14, 2002, and DSM ACC2551, on Jul. 7, 2002.

Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on Aug. 14, 2002, and DSM ACC2551, on Jul. 12, 2002.

Abstract: An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x.

Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.

Abstract: The present invention relates to a method for isolating and/or identifying stem cells having adipocytic, chondrocytic and pancreatic differentiation potential, wherein an antibody is used that binds to the antigen TNAP, alone or in combination with an antibody that binds to the cell surface antigen CD56. The invention also relates to stem cells isolated by the method according to the invention for treating defects or damages or diseases in bone or cartilage of a patient in need thereof.

Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on 14 Aug. 2002, and DSM ACC2551, on 12 Jul. 2002.

Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on 14 Aug. 2002, and DSM ACC2551, on 12 Jul. 2002.

Abstract: The present invention relates to a monoclonal antibody or fragment thereof, which binds specifically and/or selectively to human receptors of the Frizzled (FZD) family. It further relates to a hybridoma cell that produces the antibody according to the invention. Another object of the present invention is a method for the detection and/or isolation of receptors of the FZD family or homologs or fragments thereof in a biological sample and a method for the identification and/or isolation of biological material comprising or expressing receptors of the FZD family or homologs or fragments thereof. The invention further relates to the use of the antibody according to the invention or fragments thereof for the specific and/or selective detection and/or isolation of receptors of the FZD family, a composition comprising the monoclonal antibody according to the invention or fragments thereof, and a kit comprising the monoclonal antibody according to the invention or fragments thereof.

Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on Aug. 14, 2002, and DSM ACC2551, on Jul. 12, 2002.

Abstract: The invention relates to monoclonal antibodies, or fragments thereof, for isolating and/or identifying at least one cell population which is selected from the group comprising haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on Aug, 14, 2002, and DSM ACC2551, on Dec. 7, 2002.

Abstract: The present invention relates to a monoclonal antibody or fragment thereof, which binds specifically and/or selectively to human receptors of the Frizzled (FZD) family. It further relates to a hybridoma cell that produces the antibody according to the invention. Another object of the present invention is a method for the detection and/or isolation of receptors of the FZD family or homologs or fragments thereof in a biological sample and a method for the identification and/or isolation of biological material comprising or expressing receptors of the FZD family or homologs or fragments thereof. The invention further relates to the use of the antibody according to the invention or fragments thereof for the specific and/or selective detection and/or isolation of receptors of the FZD family, a composition comprising the monoclonal antibody according to the invention or fragments thereof, and a kit comprising the monoclonal antibody according to the invention or fragments thereof.

Abstract: The present invention relates to mono clonal antibodies or fragments thereof for isolating and/or identifying neural progenitor cells. The antibodies or fragments thereof bind to an identical antigen as an antibody which is produced by the hybridoma cell lines W4A5, W8C3 and 57D2 deposited on Aug. 14, 2002, at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) under the numbers DSM ACC2571, DSM ACC2570 and DSM ACC2568.

Abstract: The invention relates to a monoclonal antibody, or fragments thereof, for isolating and/or identifying mesenchymal stem cells. In this connection, the antibody, or fragments thereof, bind to an antigen which is the same as that bound to by an antibody which is produced by the hybridoma cell line W8B2, which was deposited on 14.08.2002 in the DSMZ [German collection of microorganisms and cell cultures] under the number DSM ACC2567.

Abstract: The present invention relates to monoclonal antibodies or fragments thereof for isolating and/or identifying neural progenitor cells. The antibodies or fragments thereof bind to an identical antigen as an antibody which is produced by the hybridoma cell lines W4A5, W8C3 and 57D2 deposited on Aug. 14, 2002, at the under the numbers DSM ACC2571, DSM ACC2570 and DSM ACC2568.

Abstract: Monoclonal antibodies which bind specifically to the extracellular domain of the SIRP cell surface glycoproteins, and which, in some cases, block the interaction of SIRP with the surface molecule CD47, are described.

Abstract: The present invention relates to a method for detecting allergies, with a blood sample initially being incubated with a cell-influencing agent, preferably interleukin IL-3, and then being incubated with an allergen, and with this blood sample subsequently being incubated with an antibody which binds to the surface structures on basophils and/or mast cells and/or precursor cells of basophils and/or mast cells to which the antibody 97A6 can bind, which antibody is produced and released by hybridoma cells which were deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen [German collection of microorganisms and cell cultures] GmbH, DSMZ, under number DSM ACC 2297, in accordance with the Budapest Treaty, on Dec. 2, 1997, and with the antibodies which have bound to the basophils and/or mast cells and/or precursor cells of the basophils and/or mast cells then being quantified.

Abstract: The invention relates to monoclonal antibodies, or fragments thereof, for isolating and/or identifying at least one cell population which is selected from the group comprising haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on 14.08.2002, and DSM ACC2551, on 12.07.2002.

Abstract: The present invention relates to a monoclonal antibody binding an antigen on the megakaryocytic cell line UT-7. The invention further relates to hybridoma cells producing such an antibody.